Amir Krivoy, MD, Clalit Research Institute, Tel Aviv, Geha Mental Health Center, Petah Tiqva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv; Ran D. Balicer, MD, PhD, Clalit Research Institute, Tel Aviv, Public Health Department, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva; Becca Feldman, PhD, Moshe Hoshen, PhD, Clalit Research Institute, Tel Aviv, Israel; Gil Zalsman, MD, MHA, Geha Mental Health Center, Petah Tiqva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, and Division of Molecular Imaging and Neuropathology, Department of Psychiatry, Columbia University, New York, USA; Abraham Weizman, MD, Geha Mental Health Center, Petah Tiqva, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv; Gal Shoval, MD, Clalit Research Institute, Tel Aviv, Geha Mental Health Center, Petah Tiqva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Br J Psychiatry. 2015 Apr;206(4):297-301. doi: 10.1192/bjp.bp.114.155820. Epub 2015 Feb 5.
The use of antidepressant drugs in patients with ischaemic heart disease (IHD) has been debated owing to scarcity of data and conflicting results regarding the effect of these drugs on mortality.
To evaluate the association between adherence to antidepressant therapy and all-cause mortality in a population-based cohort of patients with IHD.
A total of 63 437 patients with IHD who purchased antidepressants at least once during the years 2008-2011 were retrospectively followed for all-cause mortality over 4 years. Adherence was measured as a ratio between claimed and prescribed durations of medication and modelled as non-adherence (<20%), poor (20-50%), moderate (50-80%) and good (>80%). We used multivariable survival analyses adjusted for demographic and clinical variables that may affect mortality.
The moderate and good adherence groups had significantly reduced adjusted mortality hazard ratios of 0.83 (95% CI 0.78-0.88) and 0.86 (95% CI 0.82-0.90) respectively, compared with the non-adherence group.
Adherence to antidepressant pharmacotherapy is associated with reduced all-cause mortality in a population-based large sample cohort of patients with IHD. Physicians and health policy decision-makers should step up their efforts to sustain and enhance these patients' adherence to their antidepressant regimen.
由于关于这些药物对死亡率影响的数据稀缺且结果相互矛盾,因此一直在争论在缺血性心脏病(IHD)患者中使用抗抑郁药的问题。
在基于人群的 IHD 患者队列中评估抗抑郁药治疗依从性与全因死亡率之间的关联。
对 2008 年至 2011 年期间至少购买过一次抗抑郁药的 63437 名 IHD 患者进行回顾性随访,以评估 4 年内的全因死亡率。依从性通过所要求的和规定的药物持续时间之比来衡量,并建模为不依从(<20%)、差(20-50%)、中(50-80%)和优(>80%)。我们使用多变量生存分析,调整了可能影响死亡率的人口统计学和临床变量。
与不依从组相比,中度和良好依从组的调整后死亡率的危险比分别显著降低至 0.83(95%CI 0.78-0.88)和 0.86(95%CI 0.82-0.90)。
在基于人群的 IHD 大样本队列中,抗抑郁药治疗的依从性与全因死亡率降低相关。医生和卫生政策决策者应加强努力,维持并增强这些患者对其抗抑郁治疗方案的依从性。